谷氨胺衍生的电离性脂质使mRNA脂质纳米粒子疫苗具有更高的安全性和免疫性
Sha Li1, Lu Zheng1, Zixuan Zhang1
1Key Laboratory of Medical Molecular Virology of MOE/NHC/CAMS, School of Basic Medical Sciences & Shanghai Institute of Infectious Disease and Biosecurity & Department of Pharmacy, Shanghai Pudong Hospital, Fudan University, Shanghai 200032, China.
概括
一种新的谷氨胺衍生的电离性脂质,MOP-1,可以创建脂质纳米颗粒 (LNP),提高mRNA疫苗的稳定性,安全性和免疫激活性. MOP-1 LNP提供了卓越的传递效率和对病毒挑战的保护.
科学领域:
- 生物技术是生物技术.
- 疫苗开发 疫苗开发
- 纳米医学是一种纳米医学.
背景情况:
- 脂质纳米粒子 (LNP) -mRNA疫苗在临床上取得了成功,但在稳定性,毒性和免疫反应方面面临挑战.
- 目前的LNP平台可能会诱导过度的炎症,限制更广泛的应用.
研究的目的:
- 开发一种新的电离性脂质MOP-1,用于LNP配方,提高了输送效率,安全性和免疫性.
- 评估MOP-1 LNP作为mRNA疫苗的平台,特别是针对流感的疫苗.
主要方法:
- 合成和表征谷氨胺衍生的电离性脂质MOP-1.
- MOP-1 LNP的配方和物理化学性质的评估 (稳定性,酸解离).
- 在体外细胞毒性和体内安全性评估 (器官损伤).
- 使用流感mRNA疫苗的免疫性研究 (幽默和细胞反应).
- 对致命病毒挑战的有效性评估.
主要成果:
- MOP-1 LNPs表现出高体稳定性和高效的内体体逃生.
- 异常生物相容性,体外细胞毒性微不足道,体内无器官损伤,即使高剂量.
- MOP-1 LNP诱导了强大的幽默和细胞免疫反应,包括高中和抗体和CD8+T细胞激活.
- 在致命流感挑战模型中实现了90%的存活率和近乎完整的病毒清除.
- 优化细胞因子配置,避免过度的炎症.
结论:
- MOP-1代表了用于LNP开发的转化性电离性脂质,解决了mRNA疫苗输送中的关键局限性.
- MOP-1 LNP为开发更安全,更有效的预防和治疗疫苗提供了一个有希望的平台.
- 由于MOP-1 LNP的安全性和有效性提升,这可能会扩大mRNA疫苗技术的应用范围.
相关概念视频
02:28Leaky Scanning
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R stands for...
01:29Microorganisms in Medicine and Therapeutics
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.